Ultragenyx reports Q4 loss

Biotech company misses Wall Street expectations

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Ultragenyx Pharmaceutical Inc., a biotechnology company based in Novato, California, reported a loss of $129 million in the fourth quarter, falling short of Wall Street expectations. The company posted revenue of $207 million, surpassing analyst forecasts.

Why it matters

Ultragenyx is a prominent biotech firm focused on developing treatments for rare and ultra-rare genetic diseases. Its quarterly financial performance is closely watched by investors and industry analysts as an indicator of the company's progress and future prospects.

The details

On a per-share basis, Ultragenyx reported a loss of $1.29, missing the average estimate of $1.20 per share from 10 analysts surveyed by Zacks Investment Research. However, the company's revenue of $207 million in the quarter exceeded the $202.9 million forecast by seven analysts surveyed by Zacks.

  • Ultragenyx reported its fourth quarter results on Thursday, February 12, 2026.

The players

Ultragenyx Pharmaceutical Inc.

A biotechnology company based in Novato, California that is focused on developing treatments for rare and ultra-rare genetic diseases.

Got photos? Submit your photos here. ›

The takeaway

Ultragenyx's financial performance in the fourth quarter, while missing earnings expectations, demonstrates the challenges faced by biotech firms in bringing new treatments to market and generating consistent profitability. The company's ability to exceed revenue forecasts suggests ongoing demand for its products, but investors will be closely watching future quarters to assess the company's progress.